Repligen Corporation
RGEN | NASDAQ
$174.70
-$2.24 (-1.27%)
Nov 2, 2026, 9:47 AM ET · Market open
Company Profile
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Olivier Loeillot | President, Chief Executive Officer & Director |
| Heather Ems | Chief Information Officer |
| James R. Bylund | Chief Operating Officer |
| Jason K. Garland | Chief Financial Officer & Chief Compliance Officer |
| Anthony J. Hunt | Advisor |
| Brian Douglass | Senior VP & Chief Product Officer |
| George Scott Jr. | Senior VP & General Counsel |
| Jacob K. Johnson | Vice President of Investor Relations |
| Neil Whitfield | Senior Vice President of Sales |
| Ralf Kuriyel | Senior Vice President of Research & Development |
| Violetta Hughes | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 30, 2026 | 425 | Filing |
| Sep 28, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 425 | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 4 | Filing |
| Sep 04, 2026 | EFFECT | Filing |
| Sep 04, 2026 | 424B3 | Filing |
Repligen Corporation
| Country | United States |
| IPO Date | Apr 29, 1986 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 2,000 |
| CEO | Olivier Loeillot |
Contact Details
Building 1 Waltham,
Massachusetts 02453 United States
Stock Details
| Ticker Symbol | RGEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000730272 |
| CUSIP Number | 759916109 |
| ISIN Number | US7599161095 |
| SIC Code | 2836 |
Recent News
- 3 days ago / globenewswire.comRepligen Announces $1 Billion Private Convertible Senior Notes Transaction
- 5 days ago / seekingalpha.comRepligen Corporation (RGEN) Q3 2026 Earnings Call Transcript
- 6 days ago / marketbeat.comWhat Repligen (RGEN) Said on Its Q3 Earnings Call
- 6 days ago / zacks.comRepligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
- 6 days ago / globenewswire.comRepligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
- 19 days ago / seekingalpha.comRepligen: A Buy As Its Growth Engine Gears Up
- 20 days ago / globenewswire.comRepligen to Report Third Quarter 2026 Financial Results
- 27 days ago / gurufocus.comRepligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tells Investors
- 27 days ago / globenewswire.comRepligen Completes Acquisition of BioLife Solutions
- 28 days ago / gurufocus.comRepligen Corp (RGEN) Stock Up 4.3% but GF Value Says Overvalued -- GF Score: 85/100
Add to Watchlist
Select watchlists to add or remove RGEN